Ignite Creation Date:
2024-05-05 @ 12:02 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00218231
Status:
COMPLETED
Last Update Posted:
2017-01-12
First Post:
2005-09-16
Brief Title:
Effect of Bupropion on Smoking Behavior in Smokers With Schizophrenia
Sponsor:
National Institute on Drug Abuse NIDA
Organization:
National Institute on Drug Abuse NIDA
Study Overview
Official Title:
Transdermal Nicotine and Bupropion-SR in Schizophrenics Study 2
Status:
COMPLETED
Status Verified Date:
2008-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Many individuals with schizophrenia smoke cigarettes but little is known about the factors that control smoking in people with schizophrenia The purpose of this trial is to evaluate how bupropion an antidepressant medication affects smoking behaviors in individuals with schizophrenia who smoke
Detailed Description:
There is a high prevalence of cigarette smoking among people with schizophrenia and few smoking cessation interventions have been developed for these individuals Bupropion is an antidepressant medication commonly used to treat smoking in smokers without psychiatric disorder This study compares how smokers with schizophrenia and smokers without psychiatric illness respond to bupropion 0 300 mgday
Participants will be randomly assigned to receive either bupropion or placebo Study visits will occur after one-week treatment with placebo or bupropion During study sessions participants will come to the laboratory at 9 am and will remain abstinent in the laboratory for 5 hrs Participants will then be assessed for craving and withdrawal symptoms after viewing and handling neutral cues and smoking cues After that participants will have a 90-min period to smoke and smoking topography will be measured
Participants will be randomly assigned to receive either bupropion or placebo Study visits will occur after one-week treatment with placebo or bupropion During study sessions participants will come to the laboratory at 9 am and will remain abstinent in the laboratory for 5 hrs Participants will then be assessed for craving and withdrawal symptoms after viewing and handling neutral cues and smoking cues After that participants will have a 90-min period to smoke and smoking topography will be measured
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| DPMC | None | None | None |
| R01-14002-2 | None | None | None |